Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of florbetaben PET imaging on diagnosis and physician confidence in patients evaluated for Alzheimer's disease
2015-002606-37Phase 4Completed
- Sponsor
- Life Molecular Imaging
- Start
- Aug 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of florbetaben in Alzheimer's disease (AD) and dementia, unspecified, sponsored by Life Molecular Imaging. Primary endpoint: Change in diagnosis after florbetaben PET. Started Aug 2015; status: completed.
02
Drugs
florbetaben
03
Conditions
Alzheimer's disease (AD)dementia, unspecified
Beyond the preview
Go deeper on 2015-002606-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002606-37.